“Life sciences” is a common name of a raft of sciences dealing with living organisms and various types of life processes. The life sciences industry can be divided into several sub-groups such as Biotech & Pharma, healthcare, medical devices, research and lab services. Pharmaceuticals form the largest market sector; its sales are predicted to override USD 1 trillion by 2015.
The life sciences market proved to be rather resistant to unfavorable economic conditions. It has experienced healthy growth over the recent years on the back of the population increase, ongoing technological advancements and rising awareness of healthcare. Drug discovery, medical equipment and regenerative medicine represent the most promising market sectors.
A wealthy collection of the research reports providing extensive overview of the life sciences market is at hand in this MarketPublishers’ catalogue. Current situation and historic development of the market are reviewed in the researches. The reports thoroughly examine market segments, disclose essential information on the market size and characterize the industry dynamics and identify major forces shaping the market. Moreover, the long-term and short-term future outlooks for the market can be found in the research reports.
Publications found:
253,194
Sort by:
2018 Top 5 Pinaverium Bromide Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
US$ 4,960.00
... on the top 5 Pinaverium Bromide players in each region, with sales, price, revenue and market share from 2013 to 2018, the top players ... market share of each type, can be divided into Pinaverium Bromide 5mg Pinaverium Bromide 10mg Pinaverium Bromide 25mg Other Split by applications, this report focuses on sales ...
January 2018
122 pages
2018-2023 UK Pinaverium Bromide Market Report (Status and Outlook)
US$ 3,360.00
... the Pinaverium Bromide market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In UK market, the ... Split by product types/category, covering Pinaverium Bromide 5mg Pinaverium Bromide 10mg Pinaverium Bromide 25mg Other Split by applications/end use ...
January 2018
81 pages
2018-2023 United States Pinaverium Bromide Market Report (Status and Outlook)
US$ 3,360.00
... Pinaverium Bromide market size was xx million USD in United States, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In United States ... Split by product types/category, covering Pinaverium Bromide 5mg Pinaverium Bromide 10mg Pinaverium Bromide 25mg Other Split by applications/end ...
January 2018
81 pages
Epiomic Epidemiology Series: Refractive Errors Forecast in 18 Major Markets 2018–2028
US$ 6,800.00
Black Swan Analysis Epiomic Epidemiology Forecast Report on Refractive Errors in 18 Major Markets The main role of the optical components of the ... eye to converge the refracted rays on the retina are known as refractive errors (ametropias). The report covers the features and epidemiology facts of hyperopia, ...
January 2018
148 pages
Epiomic Epidemiology Series: Uveitis Forecast in 18 Major Markets 2018–2028
US$ 5,800.00
Black Swan Analysis Epiomic Epidemiology Forecast Report on Uveitis in 18 Major Markets Uveitis is a general term denoting a group of inflammatory conditions of the ... a country level across the 10-year forecast snapshot. Main symptoms and co-morbidities of uveitis include: Autoimmune diseases (systemic) Ocular ...
January 2018
84 pages
Acute Myeloid Leukaemia:KOL Insight
US$ 8,495.00
... they expect developers to differentiate their pipeline therapies in KOL Insight: Acute Myeloid Leukaemia. Twelve US and European KOLs give their insight on six marketed products and 13 pipeline programmes ...
January 2018
Glioblastoma: KOL Insight
US$ 8,495.00
... the market? Learn how KOLs see the glioblastoma market evolving in Glioblastoma: KOL Insight (2018). Twelve US and European KOLs provide candid insights on 3marketed and 19 ... are overwhelmingly our first go-to option in the recurrent setting for glioblastoma patients. Again, we have a bunch of those that are ...
January 2018
Market Access Impact: Melanoma (EU5) 2018
US$ 5,345.00
... help the last place brand double its share in Market Access Impact: Melanoma (EU5) [2018]. Based on a survey of 150 oncologists ... (vemurafenib; Roche) Market Access Impact: Melanoma (EU5) explores key issues affecting Melanoma drug manufacturers. You’ll learn: How barriers affect market access: What brands do ...
January 2018
Market Access Impact: Melanoma (US) 2018
US$ 5,345.00
... what your brand can do to level the playing field in Market Access Impact: Melanoma (US) [2018]. Based on a survey of 100 oncologists and ... ; Roche) Market Access Impact: Melanoma (US) [2018] explores key issues affecting melanoma drug manufacturers. You’ll learn: How barriers affect market access: What brands ...
January 2018
Medical Affairs Reputations: Psoriasis (EU5) 2018
US$ 6,365.00
... stacks up to the market leader. In the EU5, several of the psoriasis medical affairs teams we surveyed are running neck and neck ... all the ways you can improve your medical affairs services in Medical Affairs Reputations: Psoriasis (EU5). Comparing 12 major Psoriasis treatments from AbbVie, Biogen, Celgene, ...
January 2018
Medical Affairs Reputations: Psoriasis (US) 2018
US$ 6,365.00
... come out on top? In the US, nearly all of the psoriasis medical affairs teams we surveyed are running neck and neck with at least ... all the ways you can improve your medical affairs services in Medical Affairs Reputations: Psoriasis (US). Comparing 11 major psoriasis treatments from AbbVie, Amgen, Celgene, Eli ...
January 2018
MSL Teams: Field force size and structure
US$ 1,495.00
... ? The answers to these and many other questions can be found in MSL Teams: Field Force Size and Structure. This extensive market survey reveals the insights ...
January 2018
NPS+ Hepatitis C Virus (HCV) Infection US [2018]
US$ 2,655.00
... to US infectious diseases specialists and primary care physicians (PCPs) treating hepatitis C virus infection (HCV). Clearly some of these options are achieving greater levels ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by ...
January 2018
NPS+ Hepatitis C Virus (HCV)Infection (EU5) [2018]
US$ 2,655.00
... infectious diseases specialists and primary care physicians (PCPs) treating hepatitis C virus infection (HCV). Clearly some of these options are achieving greater levels of ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by ...
January 2018
Bladder Cancer: Update Bulletin #2 [February 2018]
US$ 1,095.00
... intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the ... thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer? Do KOLs hold any other concerns about dual immunotherapy combinations ...
January 2018
Breast Cancer: Update Bulletin #3
US$ 1,095.00
... events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA approval of Lynparza ...
January 2018
Chronic lymphocytic leukemia (CLL): Update Bulletin #2
US$ 1,095.00
... key opinion leader (KOL) views on recent developments in the chronic lymphocytic leukaemia (CLL) market. Topics covered include: full results from the Phase ... Imbruvica (ibrutinib; Janssen Biotech/AbbVie) in patients with high-risk CLL. Business Questions: In light of the positive results for Venclexta/Rituxan ...
January 2018
Malignant Melanoma: Update Bulletin
US$ 1,095.00
... ipilimumab for the treatment of patients with anti-PD-1 refractory metastatic melanoma; and views on the results of a Phase II study investigating ... Iovance Biotherapeutics’ LN-144 for the treatment of metastatic melanoma. Business Questions: Do KOLs anticipate the results of the EORTC1325/ ...
January 2018
Market Access Impact: Ulcerative Colitis (EU5) 2018
US$ 5,345.00
... (golimumab; Merck Sharp & Dohme) Exploring Important Market Access Issues Market Access Impact: Ulcerative Colitis (EU5) explores key issues affecting Ulcerative Colitis drug manufacturers. You’ll learn: How barriers ...
January 2018
Market Access Impact: Ulcerative Colitis (US) 2018
US$ 5,345.00
... your brand can do to level the playing field in Market Access Impact: Ulcerative Colitis (US) [2018]. Based on a survey of 100 ... Janssen Biotech) Exploring Market Access Barriers Market Access Impact: Ulcerative Colitis (US) [2018] explores key issues affecting Ulcerative Colitis drug manufacturers. You’ll ...
January 2018
Medical Affairs Reputations: Type 2 Diabetes Mellitus [Orals] (EU5) 2018
US$ 6,365.00
... the market leader In the EU5, several of the Type 2 Diabetes Mellitus medical affairs teams we surveyed are running neck and neck with ... ways you can improve your medical affair services in Medical Affairs Reputations: Type 2 Diabetes Mellitus (Orals) (EU5). Comparing 9 major Type 2 Diabetes Mellitus (Orals) ...
January 2018
Non Small Cell Lung Cancer (NSCLC): Update Bulletin #2
US$ 1,095.00
... presents key opinion leader (KOL) views on recent developments in the non-small cell lung cancer (NSCLC) market. Topics covered include: the success of the Phase ... Avastin (bevacizumab) plus chemotherapy in the first-line treatment of advanced non-squamous NSCLC at the ESMO Immuno Oncology Congress 2017; Bristol ...
January 2018
Nonalcoholic Steatohepatitis (NASH): Update Bulletin
US$ 1,095.00
... (KOLs) from North America and Europe on a variety of recent events in NASH market, including; Intercept Pharmaceuticals announcing the initiation of the global ... do KOLs say? How do KOLs arte the development of elafibranor in paediatric NASH? What concerns do experts have with elafibranor in children? What are ...
January 2018
NPS+ Haemophilia B (EU5) 2018
US$ 2,655.00
... leading brands compare to its competitors? NPS+ Haemophilia B (EU5) gives a unique insight into the ... the pack. In Europe, 2 of the 6 brands surveyed obtained a positive NPS, with one brand ... conducted the survey between February 6-19, 2018. What is Net Promoter® Score? NPS is a customer loyalty metric developed ...
January 2018
NPS+ Haemophilia B (US) 2018
US$ 2,655.00
... ‘useful but very expensive’? Explore Important Brand Loyalty Issues NPS+ Haemophilia B (US) offers valuable insight into brand loyalty from the ... in the world. We conducted the survey between February 6-19, 2018. What is Net Promoter® Score? NPS is a customer loyalty metric developed by (and a registered ...
January 2018
Systemic Lupus Erythematosus (SLE): Update Bulletin #2
US$ 1,095.00
... leader (KOL) insights on the latest events happening in Systemic Lupus Erythematosus (SLE) treatment landscape. Topics covered include expert opinions on the ... study investigating Stelara (ustekinumab; Janssen Biotech) for the treatment of SLE, and the potential for XTL Biopharmaceuticals’ edratide as well as ...
January 2018
Asia-Pacific Bio-implants Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
US$ 2,500.00
... implants, spinal implants, ophthalmic implants, structural cardiac implants, dental implants, neurostimulators implants, prosthetic implants, and others. In 2018, orthopedics & trauma segment is expected to dominate the Asia-Pacific bio-implants market with 25.6% market share ...
January 2018
391 pages
Europe Bio-implants Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
US$ 2,500.00
... implants, spinal implants, ophthalmic implants, structural cardiac implants, dental implants, neurostimulators implants, prosthetic implants, and others. In 2018, orthopedics and trauma segment is expected to dominate the Europe bio-implants market with 24.9% market ...
January 2018
391 pages
Global Bio-implants Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
US$ 4,200.00
... global bio-implants market is segmented based on product type into orthopedics & trauma, pacing devices, stents & related implants, spinal implants, ophthalmic implants, structural cardiac implants, dental implants, neurostimulators implants, prosthetic implants ...
January 2018
720 pages
North America Bio-implants Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
US$ 2,500.00
... implants, spinal implants, ophthalmic implants, structural cardiac implants, dental implants, neurostimulators implants, prosthetic implants, and others. In 2018, orthopedics and trauma segment is expected to dominate the North America bio-implants market with 24.4% market ...
January 2018
285 pages
